Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| The higher the annual sales of a branded drug, the more intense its generic erosion at patent expiry. |
 |
 |
 |
|
Pharma is facing not only a continued slow down in sales growth in the seven major markets (7MM), but the erosion of branded drugs by generics following patent expiry is also increasing, driven by evolving payer initiatives to incentivize generic use. However, the severity and speed of patients switching to generic versions of a drug is by no means equal across countries, therapy areas and formulation type, which is important when managing and forecasting branded drug sales. Tough competition, a focus on cost-containment and incentives for prescribing generic drugs make the US, UK and Germany particularly prone to severe brand erosion immediately after patent expiry, and across all markets competition amongst generic players targeting high value drugs is also fierce - leading to a rapid decline in generic prices as more players enter the market. Key findings and highlights • Tough competition, a focus on cost-containment and incentives for prescribing generic drugs, make the US, UK and Germany prone |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis